Member Info for Kevinl1977

Tommy
Glad you posted this.
‘However, the best option is to avoid this scenario altogether through rigorous upfront planning. By making sure that there is evidence of strong pathophysiological and mechanistic underpinnings that are common to both the new therapy and the disease, by selecting appropriate patients and end points, by calculating an adequate sample size, by paying meticulous attention to dosing, definitions of disease and outcomes, and all procedural processes, and by anticipating the ways in which the trial might fail and give rise to criticisms, one can enhance the likelihood of reaching a decisive conclusion.
Was meticulous attention paid to dosing?

Sativa
News without delay doesn’t necessarily mean that it won’t be long in coming to fruition.
It means that once this is complete, there will be no delay in reporting it, as per stock exchange trading rules.
Anyones guess is how long it will take, as we know they are not the quickest company at delivering the goods.

Thanks Titania.

Bryso
Pretty much sums up most long term investors strategy, I would think.
ATB

Wonga
That was my question to Brooke shields, for which I’m awaiting a reply.
That was my concern, as you rightly stated.
ATB

Yes, many thanks to Tommy in particle their efforts.
I was encouraged by the following, posted yesterday:
‘In addition to monitoring drug safety, the lifecycle evaluation approach enables regulators to approve drugs based on clinical evidence that is less robust, with the understanding that drugs will continue to be evaluated after approval.’
This sounds like a possibility for us. Pretty sure if we were a major pharma we would have applied already.
I’m sure that RM’s knowledge is tip-top as to the possibilities at our disposal.
ATB

Spred
We’re obviously not worthy of your presence.
As the chosen one, why don’t you stay around and improve the quality on the board. You could then astound us with your quality posts.

Tatty
You’re Probably right :)
Emotions are running high, as we have no leading light fronting up on behalf of the company.
Normally, a leader will step up when these situations occur.
We keep soldiering on.

Manifesto
No, nothing as yet but I’ll let you know as soon as I receive something.
ATB

Skippy
There were positives in our RNS, but they became largely lost in the opening sentences.
I’m pretty sure it could have been spun out differently using a more positive spin. I/v potent against delta and omicron, positive quantitative data that was in there, hidden away.
Let’s face it, I remember the video RM did with the scientists way back; it was Boring!
We all tried to glam it up but the negativity shines through with him, always on the negative.
This is now where he earns his corn, for me.
I would have liked to have seen him in a short video to investors, immediately. He may have echoed what was in the RNS, but he could have focussed on the positives remaining and reinforced Synairgen investors that we are still invested in the right company.
What’s the worst that could have happened, the SP could t go much lower following the RNS.
Regardless of this, I’m still all in and hoping that we can pull through.
ATB

Manifesto
That’s a big buy.
Imagine if a buy that big was made pre-RNS.
People on here would be all over it.
I think we can guess who made that.

Burstead
I only see green where you’re concerned, thankfully.
Buzz off :)

Andy
We don’t agree on many things, as I think we are two completely different characters.
However, the only thing I do agree with you on is that we have a very poor and out-of-his-depth CEO, imo. He’s not a leader is he!
I have no option but to remain invested here, as the loss would be too big to take.
I don’t think people are ramping this stock, but are trying to focus on the positives that we still have left and I’m very grateful for some of the excellent posters on here.
If the data from the deep dive and A2 is not strong, then we are doomed. We will know our outcome in the next couple of months, for sure.
It’s not over yet, there’s always a way!
I hope you are able to nurse your losses, as I don’t wish ill on anyone.
ATB

The primary efficacy endpoint for Part B of the study is more than three out of 30 patients per tumor group achieving clinical benefit, defined as complete response, partial response, or stable disease for at least six months.
Part B of the study has to date enrolled 20 patients with RCC, of which four out of the first 16 have shown to achieve clinical benefit.
Compare this to our own results. Although endpoints weren’t met The SPRINTER trial pointed to an encouraging trend in prevention of progression to severe disease and death (36% reduction in the pre-defined per protocol population), which the Company and its clinical advisors strongly believe merits further investigation.
What would a positive spin on the RNS have done to our SP, especially given the excellent potent I/v results that have been lost in the poorly communicated company response?

Agreed TL.

There was an article shared here last week which highlighted the differences in SOC across the various countries. India was highlighted and compared to how they deliver treatments. There were marked difference in timelines for treating patients l; this would inevitably affect recovery success.
Manifesto - I believe that once market sensitive news is received, it has to be RNSd, by law.

The point is, the results were poor yet, when you read the RNS it comes across as positive. Hence, the large rise.
The SP pre-RNS is irrelevant.
If the RNS stated poor results, there would be a drop regardless.

Or the ones who didn’t receive our drug until several days in!

James
Agreed, just read it and only the positives are the focus.
Results were very poor if you look at the % improvements. Between 10-25% in both scenarios, but the SP has risen 30% today.
Interesting, without a doubt.

Andy
I feel your frustration, join the club.
I’m intrigued as to what your opinion is of Polygon and why they continue to buy at the current prices?
Have they got it wrong?
Do they know something we don’t?
Do they want control over the board?
With the amount of shares they have, averaging down enough would be impossible and would take another enormous investment layout.
Regards